Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Pilot Study Of The Effect Of Rifaximin On B-cell Dysregulation In Cirrhosis Due To Chronic Hepatitis C Infection

Next Previous
X
Search
Trial Profile

Prospective Pilot Study Of The Effect Of Rifaximin On B-cell Dysregulation In Cirrhosis Due To Chronic Hepatitis C Infection

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Bacterial infections; Intestinal infections
  • Focus Pharmacodynamics

    • Most Recent Events

    • 08 Mar 2021 Status changed from active, no longer recruiting to discontinued due to inadequate enrollment prior to expiration date of unreplaceable blinded investigational product.
    • 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
    • 26 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top